Effect of DNMT SNPs on DNA Methylation in Primary ITP

NCT04100876 | Unknown DMC

• 1 other identifier: DNA methylation in Primary ITP
• Study Type: observational
• Target: 90
• Locations: 0 countries
• Sites: N/A

Brief Summary

• To compare global DNA methylation status between ITP patients and healthy subjects .
• To determine the effect of DNMT3A -448 G/A SNP variant A allele and DNMT3B -149C/T SNP variant T-allele on global DNA methylation in both ITP patients and healthy control subjects.

Conditions

Primary Immune Thrombocytopenia

Outcome Measures

Primary Outcomes (1)

• Comparison of global DNA methylation status between ITP patients and healthy subjects .

  To understand the underlying mechanism behind the association of DNMT3A -448 G/A SNP variant A allele with decreased risk of primary ITP and DNMT3B -149C/T SNP variant T-allele with increased risk of primary ITP which was observed in a previous study in Assiut University Hospital (AbdelKader et al., 2018).

  baseline .

Study Arms (2)

primary ITP patients .

60 primary ITP patients .

Genetic: Global DNA methylation will be quantified in the DNA samples by colorimetry

healthy subjects .

30 healthy age and sex matched control subjects .

Genetic: Global DNA methylation will be quantified in the DNA samples by colorimetry

Interventions

Global DNA methylation will be quantified in the DNA samples by colorimetry GENETIC

Global DNA methylation will be quantified in the DNA samples by colorimetry

healthy subjects .; primary ITP patients .

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

: 60 primary ITP patient and 30 healthy age and sex matched control subjects .

You may qualify if:

• Egyptian patients with isolated thrombocytopenia, no organomegaly or lymphoadenopathy, no constitutional symptoms (bone pains, weight loss, and night sweats) and no history of preceding drug intake (quinine, heparin) .

You may not qualify if:

• Conditions/diseases associated with secondary ITP.

Sponsors & Collaborators

• Assiut University: lead

Biospecimen

Retention: SAMPLES WITH DNA

Study will be conducted on DNA samples (available from previous study of AbdelKader et al., 2018) with known DNMT3A -448 G/A and DNMT3B -149C/T genotypes.

MeSH Terms

Conditions

Purpura, Thrombocytopenic, Idiopathic

Condition Hierarchy (Ancestors)

Purpura, Thrombocytopenic; Purpura; Blood Coagulation Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Thrombotic Microangiopathies; Thrombocytopenia; Blood Platelet Disorders; Cytopenia; Hemorrhagic Disorders; Autoimmune Diseases; Immune System Diseases; Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Skin Manifestations; Signs and Symptoms

Study Officials

• Heba A Abdel-Hafeez, Professor

  Clinical Pathology Department in Assuit University Hospital

  STUDY DIRECTOR

Central Study Contacts

Mennat-Allah A Mahmoud, physician

CONTACT

01006044750; Mennanaser121993@gmail.com

Tarek TH ElMelegy, Lecturer

CONTACT

01095472946; t_elmelegy@yahoo.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Pathology Department

Study Record Dates

• First Submitted: September 23, 2019
• First Posted: September 24, 2019
• Study Start: December 1, 2019
• Primary Completion: October 1, 2021
• Study Completion: December 1, 2021
• Last Updated: September 24, 2019

Record last verified: 2019-09